---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005446"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:26:29.194699+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapport accelerates Phase 3 start for RAP-219 in focal seizures to Q2 2026; expands epilepsy portfolio into PGTCS

## Summary
- Phase 3 program for RAP-219 in focal onset seizures accelerated to Q2 2026 (from Q3) after FDA End-of-Phase 2 meeting.
- New epilepsy program in primary generalized tonic-clonic seizures (PGTCS); Phase 3 trial planned H1 2027.
- FDA removed clinical hold on DPNP IND; Rapport defers further DPNP investment to prioritize α6β4 program.
- $513M cash, cash equivalents and short-term investments as of Q3 2025; expected to fund operations into H2 2029.
- Phase 2 bipolar mania trial on track for H1 2027 topline; long-acting injectable IND-enabling activities start Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-005446
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/0001193125-26-005446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526005446/rapp-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005446
- JSON: https://secwatch.observer/filing/0001193125-26-005446.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.